Weekly roundup: An A* week. Agreements, appointments, and all things ADCs
With just over a week to go until London Life Sciences Week, the excitement is building and the events schedule is overflowing with opportunities to connect with the key players of the life sciences industry.
A big thank you to Nnenna Ohaka for her article covering Optimum’s Healthcare Investor Conference in BioXconomy this week! Sharing insights from an excellent and candid panel session on ‘Everything you wanted to know on how to have the best exit to pharma (but were too afraid to ask)’.
AmacaThera signs exclusive global licensing agreement with Pacira BioSciences for up to US$230 million, validating its tunable drug delivery platform
AmacaThera, a leading developer of next generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, announced an exclusive worldwide licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, for the development and commercialization of AMT-143, an investigational long-acting non-opioid anaesthetic for post-operative pain.
Amber Implants appoints Vincent Gardès as Chief Executive Officer to Drive Commercial Launch of VCFix® Spinal System
Experienced MedTech leader to guide Amber Implants’ transition from development into commercialisation following FDA clearance of the VCFix® Spinal System. The Company is preparing for U.S. market launch in 2026.
Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Groundbreaking research from Nucleome founder and Oxford University, which uses Micro Capture-C (MCC) technology for the first time to reveal the complex structure of DNA inside living cells at base pair resolution, has been published in Cell. Nucleome has an exclusive license for MCC from Oxford University and has applied the technology to decipher the molecular basis of inflammatory diseases from thousands of non-coding disease-associated genetic variants in patients.
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Heidelberg Pharma, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced that its lead ATAC Candidate, HDP-101, demonstrated further clinical activity in Cohort 8, including stringent complete remission in two patients from Cohort 8. The data was presented at the at the 16th Annual World ADC Congress, in San Diego, California. Heidelberg Pharma will host an R&D Webinar to discuss these findings on 11 November 2025 at 05:00 pm CET (08:00 am PST).
For further information on the R&D webinar, or to register your attendance, please use the link here.
Tulyp Medical emerges from Sofinnova’s medtech accelerator and announces FDA submission following initial first-in-human use
Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. FDA. Backed by Sofinnova’s MD Start, Tulyp is led by experienced medtech entrepreneurs and cardiologists and debuts following positive results from its initial first-in-human study.
Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
Resolution Therapeutics, a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, announced new clinical and preclinical data being presented during the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2025 (7-11 November, Washington D.C). These data strongly support the hypothesis that Regenerative Macrophage Therapy (RMT) has anti-inflammatory and anti-fibrotic effects in cirrhosis.
🎙️Optimum Perspectives Podcast
‘The ups and downs of ADCs – where to now?’
Just in time for #WorldADC San Diego 2025 – a brand new episode with elite guests Francois Bertelli of DISCO Pharmaceuticals GmbH, Stefano Gullà of Kling Biotherapeutics, and Michael Karl Bauer of Novo Holdings, as they dive into the hot topic of ADCs!
Expect sharp insights and forward-looking perspectives on the evolving ADC landscape. Listen to the full episode here: https://www.optimumcomms.com/podcast/#episode35
✏️ In the news
From “win-win or no deal”, to the secret of being unforgettable, and why timing is both everything and nothing – our panellists didn’t hold back. Read Nnenna Ohaka‘s article in BioXconomy outlining the top takeaways from Optimum’s conference panel session ‘Everything you wanted to know on how to have the best exit to pharma (but were too afraid to ask)’.
Read the full article here: https://lnkd.in/e5ReGRgB
🔥Hot topic
The UK just made a major move in #RareDisease that could reshape where companies choose to develop breakthrough therapies. For the 3.5 million people in the UK with a rare disease – 95% without approved treatments – this regulatory shift could be transformative. Read our latest #HotTopic here ⬇️
👥Upcoming events
Jefferies & LSX Investival – London Life Sciences Week 2025
Europe’s biggest week in life sciences is just around the corner, are you ready? Optimum Strategic Communications and Catalyst Advisors have teamed up to help you make the most of every meeting, mixer, and moment.
👉 Download our events schedule to be in the right place at the right time to build valuable connections. Know of an event we should include? Please let us know at marketing@optimumcomms.com
If you’ve not yet registered for LSX Investival there is still time, but be quick! To use Optimum’s 15% discount code email us on contact@optimumcomms.com
🧩 Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
